Cancer glossary
Pembrolizumab (Keytruda): how it works, who gets it and side effects
Pembrolizumab is an immunotherapy drug, a PD-1 inhibitor. How it works, which cancers it treats, how often it is given and which side effects need an urgent call to your doctor.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
Pembrolizumab (brand name Keytruda) is an immunotherapy drug from the group of immune checkpoint inhibitors. It blocks the PD-1 protein on immune cells, and they start attacking the tumor more actively.
How it appears in your prescription
- ‘Pembrolizumab 200 mg IV every 21 days’ or ‘400 mg every 42 days’.
- ‘Pembrolizumab + platinum-based chemotherapy’ — a common option in lung cancer.
- ‘Adjuvant pembrolizumab’ — treatment after surgery to lower the risk of the cancer coming back.
What it means
A tumor can ‘switch off’ the immune attack through the PD-1 and PD-L1 pair. Pembrolizumab breaks that link. According to the US National Cancer Institute, it is approved for many cancers: melanoma, non-small cell lung cancer, head and neck, bladder, kidney, stomach and esophageal, cervical and endometrial cancer, triple-negative breast cancer, and any solid tumor with high microsatellite instability (MSI-H/dMMR). Approved uses in each country are set by the local label and guidelines.
Side effects
The most common are fatigue, itching and rash, diarrhea and changes in thyroid function. Immunotherapy has its own specific risk — immune-related adverse events: inflammation of the bowel, liver, lungs or hormone glands. They can appear at any point during treatment and even after it ends. That is why blood tests, including thyroid hormones and liver tests, are done before each infusion.
Tell your doctor straight away if you have diarrhea more than 4–6 times a day, a cough or shortness of breath, severe weakness with dizziness, or yellowing of the skin.
Questions to ask your doctor
- What is the aim of treatment: after surgery or for advanced disease?
- How long will immunotherapy last and how will the effect be assessed?
- Which tests are needed before each infusion, and whom do I call about side effects?
More in the articles on immunotherapy and its side effects.
Sources
- Pembrolizumab — National Cancer Institute
- Side Effects of Immunotherapy — National Cancer Institute
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update — ASCO, 2021
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
